Portfolio company CorFlow Therapeutics completed Phase 1 and enrolled first patients in Phase 2 of its MOCA II pivotal trial, and gained approval to start the REVITALISE RCT in Europe.
CorFlow Therapeutics is developing the CoFI (Controlled Flow Infusion) System, a medical device designed to diagnose microvascular obstruction (MVO) in real-time during percutaneous coronary intervention (PCI) and serve as a treatment platform in the cath lab
CorFlow Therapeutics is developing the CoFI (Controlled Flow Infusion) System, a medical device designed to diagnose microvascular obstruction (MVO) in real-time during percutaneous coronary intervention (PCI) and serve as a treatment platform in the cath lab.